Compare · NTLA vs QUIT

NTLA vs QUIT

Side-by-side comparison of Intellia Therapeutics Inc. (NTLA) and Achieve Life Sciences Inc. (QUIT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NTLA and QUIT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • NTLA is the larger of the two at $1.34B, about 2.1x QUIT ($645.9M).
  • NTLA has been more active in the news (17 items in the past 4 weeks vs 1 for QUIT).
  • NTLA has more recent analyst coverage (25 ratings vs 0 for QUIT).
MetricNTLAQUIT
Company
Intellia Therapeutics Inc.
Achieve Life Sciences Inc.
Price
-
-
Market cap
$1.34B
$645.9M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2016
News (4w)
17
1
Recent ratings
25
0
NTLA

Intellia Therapeutics Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

QUIT

Achieve Life Sciences Inc.

AchieveRx, The Quit Company (Nasdaq: ACHV; QUIT effective November 10, 2026 ; formerly doing business as Achieve Life Sciences, Inc. ) is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx's mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good.